![Penumbra, Inc. logo]()
|
|
BSIR 2023
Visit Penumbra at Booth 25 to Learn More
|
![STRIDE STUDY]()
|
A Study of Patients with Lower Extremity Acute Limb Ischemia to Remove Thrombus with the Indigo™ Aspiration System (including Lightning™ Technology)
|
STRIDE Study | 30-day Data
DATA NOT YET PUBLISHED, PRESENTED AT CHARING CROSS 20231
| |
STRIDE
Indigo System |
Open Surgical
Revascularisation |
Mortality
(at 30 days) |
3.4% |
13.2 2, b |
Target Limb Salvage
(at 30 days) |
98.2% |
83.1 3, a, b |
Indigo Aspiration Time
(Median) |
22 minutes |
— |
|
Are you interested in learning more about the advantages of firstline management of ALI with endovascular Mechanical Aspiration Thrombectomy?
|
![case images]()
Popliteal and Below-the-Knee Occlusion
Prof. Gianmarco de Donato, University of Siena, Italy
|
1. Lyden SP. High limb salvage rate & low mortality: 30-day data from the STRIDE study. Presented at: Charing Cross International Symposium 2023; 25 April, 2023; London, UK.
2. Taha AG, Byrne RM, Avgerinos ED, et al. Comparative effectiveness of endovascular versus surgical revascularization for acute lower extremity ischemia. J Vasc Surg. 2015 Jan;61(1):147–54. doi:10.1016/j.jvs.2014.06.109.
3. Veenstra EB, van der Laan MJ, Zeebregts CJ, et al. A systematic review and meta-analysis of endovascular and surgical revascularization techniques in acute limb ischemia. J Vasc Surg. 2020 Feb;71(2):654–668.e3. doi:10.1016/j.jvs.2019.05.031.
a. Composite limb salvage rate at 30 days calculated and data on file at Penumbra, Inc.
b. Data cannot be directly compared. Please refer to specific publications for detailed patient and data collection methods.
|
![X]()
![spacer]()
![LinkedIn]()
|
Images used with permission. Consent on file at Penumbra, Inc. The clinical results presented herein are for informational purposes only, and may not be predictive for all patients. Individual results may vary depending on patient-specific attributes and other factors.
Product availability varies by country. Prior to use, please refer to the Instructions for Use (IFU) for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. Please click here to view the complete IFU Summary Statements. Please contact your local Penumbra representative for more information.
Copyright �2023 Penumbra, Inc. All rights reserved. The Penumbra P logos, STRIDE logo, Indigo, and Lightning are registered trademarks or trademarks of Penumbra, Inc. in the USA and other countries. 28246, Rev. A 10/23 OUS
|
|
|
|
